Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening System
← catalyst calendarNCT07758907 · readout ≤ 12 d
Sponsored by Intelligent Bio Solutions Inc. (industry) · INBS — their whole pipeline →. With CenExel.
Phase
Not applicable
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Other
Enrollment
95estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-15 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Interference With Routine Analytical Tests
- Stability of in Vitro Diagnostic Reagents
- Illicit Drug Use
Interventions
- Device: Device storage condition
- Device: Interferent application
Primary outcome
what the primary-completion date above is the date OFEffect of Potential Interferents
measured For exogenous interferent contact within 15 minutes prior to fingerprint sweat specimen collection.
Permalink · INBS's whole pipeline · Catalyst calendar · Every registered study · What changed